Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
Zongbi YiZongbi YiGuohua RongYanfang GuanChunxiao LiBing-He XuPublished in: Cancer communications (London, England) (2020)
TP53 mutations in exons 5-8 may be an independent prognostic marker for short DFS in patients with metastatic breast cancer. TP53 mutations had opposite effects on trastuzumab-treated patients treated with and without taxanes.